GlassScriptPhysician profile
Christopher William Weyer
NPI 1851515381
$4,267.23
in general payments reported to CMS, 2019-2025
26 companies · $448 in 2025
The $448 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,229 · 2020: $239 · 2021: $509 · 2022: $595 · 2023: $589 · 2024: $657 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $867.83 | 2021-2025 | Botox, Alloderm |
| Allergan, INC. | $596.49 | 2019-2022 | |
| Sientra, INC. | $505.37 | 2021-2022 | |
| Biofrontera INC. | $466.04 | 2019 | |
| Apyx Medical Corporation | $415.28 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $259.62 | 2023-2025 | Libtayo |
| Integra Lifesciences Corporation | $178.21 | 2019-2025 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Genzyme Corporation | $157.82 | 2019-2025 | |
| Smith+Nephew, INC. | $148.99 | 2023 | Grafix Pl |
| W. L. Gore & Associates, INC. | $123.42 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Revance Therapeutics, INC. | $101.88 | 2025 | Daxxify |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $75.56 | 2019 | |
| Incyte Corporation | $49.71 | 2022-2023 | Opzelura |
| Dusa Pharmaceuticals, INC. | $45.87 | 2019 | |
| Misonix INC | $41.67 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $40.03 | 2022 | |
| Lilly USA, LLC | $37.74 | 2019-2020 | |
| Leo Pharma INC. | $32.28 | 2025 | Anzupgo |
| Novartis Pharmaceuticals Corporation | $25.38 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $20.41 | 2022 | |
| Sun Pharmaceutical Industries INC. | $16.76 | 2022 | |
| Janssen Biotech, INC. | $14.43 | 2025 | Stelara, Tremfya, Simponi Aria |
| Johnson & Johnson Surgical Vision, INC. | $14.22 | 2019 | |
| Galderma Laboratories, L.P. | $14.08 | 2019 | |
| Mentor Worldwide LLC | $13.18 | 2021 | |
| Organogenesis INC. | $4.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Weyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.